Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war!

Affiliations

¹ Institute of Lung Diseases, Sremska Kamenica, Kragujevac, Serbia;; BioIRC Centre for Biomedical Research, Kragujevac, Serbia;
² Department of Radiation Oncology, Inselspital, Bern, Switzerland ;
³ University Hospital to East Slovakia Institute of Oncology, Kosice, Slovakia.
⁴ BioIRC Centre for Biomedical Research, Kragujevac, Serbia;

Editorial

Branislav Jeremic et al. J Thorac Dis. 2016 Aug.

. 2016 Aug;8(8):1886-90.

doi: 10.21037/jtd.2016.07.11.

¹ Institute of Lung Diseases, Sremska Kamenica, Kragujevac, Serbia;; BioIRC Centre for Biomedical Research, Kragujevac, Serbia;
² Department of Radiation Oncology, Inselspital, Bern, Switzerland ;
³ University Hospital to East Slovakia Institute of Oncology, Kosice, Slovakia.
⁴ BioIRC Centre for Biomedical Research, Kragujevac, Serbia;

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N. Vansteenkiste JF, et al. Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27. Lancet Oncol. 2016. PMID: 27132212 Clinical Trial.

1. International Agency for Research on Cancer (IARC). Available online: http://globocan.iarc.fr
1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. 10.1097/JTO.0b013e31812f3c1a - DOI - PubMed
1. Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 2013;31:3320-6. 10.1200/JCO.2013.51.1816 - DOI - PMC - PubMed
1. Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2015;33:4007-14. 10.1200/JCO.2015.61.8918 - DOI - PubMed